4503 On Other Exchanges
Symbol
Exchange
4503 is not on other exchanges.

astellas pharma inc (4503) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports/exports pharmaceutical products worldwide. The company offers Prograf, an immunosuppressant for the prevention of rejection in organ transplants; Vesicare, a treatment for overactive bladder; Protopic, a treatment for atopic dermatitis in the topical immunomodulator class; Harnal, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, a COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment for hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, a 5-HT3 receptor antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. In addition, the company offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI. It has collaboration agreements with The University of Texas MD Anderson Cancer Center; Potenza Therapeutics, Inc.; Kanyos Bio, Inc.; Chromocell Corporation; and Ocata Therapeutics, Inc. The company also has license agreement with Immunomic Therapeutics, Inc.; collaborative research agreement with the National Institute of Advanced Industrial Science and Technology; and collaborative development agreement with the Institute of Medical Science, the University of Tokyo. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

17,217 Employees
Last Reported Date: 06/20/16
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥216.0M
Chief Administrative Officer, Chief Complianc...
Total Annual Compensation: ¥108.0M
Compensation as of Fiscal Year 2016.
astellas pharma inc
Astellas Pharma Inc. Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs

Astellas Pharma Inc. announced that it exercised its right to terminate the agreement executed as of September 21, 2010 between Astellas and UMN Pharma Inc. for the co- development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan.

Sysmex, Astellas, and Daiichi Sankyo Sign Memorandum of Understanding to Create Method for Analysing Circulating Tumour Cells

Sysmex, Astellas Pharma, and Daiichi Sankyo have signed a memorandum of understanding (MoU) to create a method for analysing circulating tumour cells (CTC). Under the agreement, the companies will focus on creating a novel CTC analysis method, focusing on liquid-biopsy-based diagnostics and treatments, as well as encourage the uptake of CTV analysis in clinical settings. Financial details were not disclosed.

Amgen Astellas Biopharma K.K. and Astellas Pharma Inc Announces Submission of Application for Investigational Osteoporosis Medication Romosozumab in Japan

Amgen Astellas BioPharma K.K. and Astellas Pharma Inc. announced that Amgen Astellas submitted an application seeking marketing approval of romosozumab (AMG785) for the treatment of osteoporosis for those at high risk of fracture for review to the Ministry of Health, Labour and Welfare in Japan. Amgen Astellas and Astellas are co-developing romosozumab in Japan. Romosozumab is an investigational monoclonal antibody that works by binding and inhibiting the activity of sclerostin, a glycoprotein secreted by osteocytes in bone, thereby increasing bone formation and decreasing bone resorption.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4503.
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 14.2x
Price/Sales 2.2x
Price/Book 2.4x
Price/Cash Flow 12.0x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.